Why pharmacy deserves a year-round management strategy

Employer pharmacy strategy is not a once-a-year formulary conversation. It is a purchasing, clinical and employee-experience discipline that determines how the plan pays for medicines, how members access them and which incentives shape those decisions. Pharmacy deserves its own management cadence because a small set of therapies, channel choices or contract definitions can materially change both spend and member friction.

The starting point is a net-cost view. Leaders need to see ingredient cost, dispensing fees, administrative charges, rebates, fees retained by vendors, specialty distribution economics and the member’s out-of-pocket experience together. A gross rebate figure is not a strategy. The meaningful question is what the employer paid after every credit, fee and concession—and whether that result supports clinically appropriate access.

PBMs can be paid in several ways. Some arrangements use transparent administrative fees; others earn income through retail network spreads, specialty dispensing, rebate retention or manufacturer and pharmacy payments. None should be assumed from a proposal summary. Ask each vendor to identify every source of compensation, the entity receiving it, the formula used and the employer’s right to reconcile the result against claims and invoice data.

Spread pricing means the amount charged to the plan for a prescription exceeds the amount paid to the dispensing pharmacy, with the difference retained by the PBM or an affiliate. It can occur in retail, mail and specialty channels. The issue is not a label; it is whether the contract makes the definition, calculation and retained amount visible. A plan cannot govern economics it cannot see.

Rebates can lower net cost, but they can also distort purchasing if they become the primary decision measure. A drug with a high list price and a large rebate may still cost more after the rebate than an available alternative. Employers should evaluate net cost, clinical appropriateness, disruption risk and access at the therapy-class level rather than rewarding the largest reported rebate check.

Specialty drug management requires a deliberate sourcing strategy. Review whether specialty prescriptions must use a PBM-owned pharmacy, whether alternate channels can be evaluated, how limited-distribution drugs are handled and what patient-support programs are available. Establishing a clinical and financial review before a specialty claim accelerates is generally more useful than examining the bill after it has become the year’s largest expense.

GLP-1 management deserves a specific policy discussion, not a generic utilization rule. Leadership should understand the covered indications, prior-authorization criteria, continuation requirements, lifestyle or clinical support, anticipated utilization and the experience members have when coverage changes. The objective is neither unrestricted coverage nor a blunt exclusion; it is a policy that is clinically coherent, consistently administered and financially understood.

Biosimilars create another decision point. A high-performing approach assesses the clinical evidence, prescriber and member communication, formulary positioning, site of care and net-cost implications before utilization shifts. Success is measured by appropriate adoption with clear support—not simply by adding a product to a list.

PBM audit rights turn a contract promise into a governable standard. Contracts should define data access, audit scope, timing, record retention, the employer’s ability to use an independent reviewer and remedies when performance cannot be substantiated. Audit provisions that are too narrow, too delayed or controlled by the party being audited are not a meaningful accountability mechanism.

Contract guarantees should be treated as operating commitments. Define the baseline, the measurement method, exclusions, reporting cadence and financial remedy for each guarantee. Review performance quarterly, not after the plan year closes. A guarantee is useful only when leadership can determine whether it was achieved and what happens when it was not.

A quarterly pharmacy dashboard should connect cost and care. Include net cost per prescription, specialty share of spend, top therapy-class movement, rebate pass-through and reconciliation status, generic and biosimilar adoption, GLP-1 utilization, prior-authorization outcomes, member disruption and each contract guarantee. Every metric should have an accountable owner and a decision it is intended to inform.

Start with four questions for your PBM: What compensation is retained beyond the stated fee? How is each rebate defined, allocated and reconciled? What specialty and alternative-sourcing options can the employer evaluate? What audit rights and remedies apply when reported results cannot be verified? Those answers create the foundation for a pharmacy strategy that can be managed throughout the year rather than renewed on trust.